[{"AccountsPayableCurrent_0_Q3_USD":21251.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-456326.0,"NetIncomeLoss_1_Q3_USD":6544315.0,"NetIncomeLoss_3_Q3_USD":-25296000.0,"NonoperatingIncomeExpense_1_Q3_USD":8726631.0,"NonoperatingIncomeExpense_3_Q3_USD":-22877613.0,"NotesPayableRelatedPartiesClassifiedCurrent_0_Q3_USD":134296.0,"OperatingIncomeLoss_1_Q3_USD":-2182316.0,"OperatingIncomeLoss_3_Q3_USD":-2418387.0,"OtherDeferredCostsNet_0_Q3_USD":70000.0,"PaymentsOfFinancingCosts_3_Q3_USD":11551067.0,"PaymentsToAcquireInvestments_3_Q3_USD":552000000.0,"PreferredStockParOrStatedValuePerShare_0_Q3_USD":0.0001,"PreferredStockSharesAuthorized_0_Q3_shares":1000000.0,"PreferredStockSharesIssued_0_Q3_shares":null,"PreferredStockSharesOutstanding_0_Q3_shares":null,"PreferredStockValue_0_Q3_USD":null,"PrepaidExpenseCurrent_0_Q3_USD":87249.0,"StockRedeemedOrCalledDuringPeriodValue_1_Q3_USD":1068009.0,"StockIssued1_3_Q3_USD":25000.0,"StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0_Q3_USD":-72173154.0,"StockholdersEquity_0_Q3_USD":-72173154.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":-72174534.0,"ReimbursementFromLimitedPartnershipInvestment_3_Q3_USD":1104000.0,"NetCashProvidedByUsedInInvestingActivities_3_Q3_USD":-552000000.0,"ProfitLoss_1_Q3_USD":6544315.0,"ProductionTaxExpense_1_Q3_USD":49863.0,"ProceedsFromRepaymentsOfRelatedPartyDebt_3_Q3_USD":-200000.0,"ProceedsFromRelatedPartyDebt_3_Q3_USD":149000.0,"ProceedsFromIssuanceOfWarrants_3_Q3_USD":17995200.0,"ProceedsFromIssuanceOfPrivatePlacement_3_Q3_USD":13040000.0,"ProceedsFromIssuanceInitialPublicOffering_3_Q3_USD":552000000.0,"ProductionTaxExpense_3_Q3_USD":134297.0,"NetCashProvidedByUsedInFinancingActivities_3_Q3_USD":554541933.0,"LiabilitiesCurrent_0_Q3_USD":2119311.0,"LiabilitiesAndStockholdersEquity_0_Q3_USD":554188289.0,"DerivativeGainLossOnDerivativeNet_3_Q3_USD":-1006114.0,"DerivativeGainLossOnDerivativeNet_1_Q3_USD":35990.0,"DeferredIncomeNoncurrent_0_Q3_USD":19320000.0,"CommonStockValue_0_Q3_USD":null,"CommonStockNoParValue_0_Q3_USD":0.0001,"CommitmentsAndContingencies_0_Q3_USD":null,"DerivativeLiabilitiesNoncurrent_0_Q3_USD":52922132.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_3_Q3_USD":2085607.0,"Cash_0_Q3_USD":2100000.0,"AssetsHeldInTrust_0_Q3_USD":552015433.0,"AssetsCurrent_0_Q3_USD":2172856.0,"Assets_0_Q3_USD":554188289.0,"AdditionalPaidInCapital_0_Q3_USD":null,"AccruedLiabilitiesCurrent_0_Q3_USD":1963764.0,"CashAndCashEquivalentsAtCarryingValue_0_Q3_USD":2085607.0,"TemporaryEquityAccretionToRedemptionValueAdjustment_3_Q3_USD":46902154.0,"FairValueAdjustmentOfWarrants_1_Q3_USD":-8682667.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1_Q3_USD":3825067.0,"Liabilities_0_Q3_USD":74361443.0,"IssuanceOfStockAndWarrantsForServicesOrClaims_3_Q3_USD":15213332.0,"InvestmentIncomeInterest_3_Q3_USD":15433.0,"InterestIncomeOther_3_Q3_USD":15433.0,"InterestIncomeOther_1_Q3_USD":7974.0,"IncreaseDecreaseInPrepaidExpense_3_Q3_USD":87249.0,"FairValueAdjustmentOfWarrants_3_Q3_USD":6673600.0,"IncreaseDecreaseInAccruedLiabilities_3_Q3_USD":1893764.0,"GeneralAndAdministrativeExpense_3_Q3_USD":2284090.0,"GeneralAndAdministrativeExpense_1_Q3_USD":2132453.0,"GainLossOnSaleOfDerivatives_1_Q3_USD":null,"GainLossOnSaleOfDerivatives_3_Q3_USD":-15213332.0,"FranchisorCosts_3_Q3_USD":134296.0,"FederalDepositInsuranceCorporationPremiumExpense_3_Q3_USD":250000.0,"IncreaseDecreaseInAccountsPayable_3_Q3_USD":21250.0,"TemporaryEquityCarryingAmountAttributableToParent_0_Q3_USD":552000000.0,"Ticker":"EQRX","CIK":"1843762","name":"CM LIFE SCIENCES III INC.","OfficialName":"EQRx Inc.  Common Stock","form":"10-Q","period":"20210930","fy":"2021.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"2184594115.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20211115"}]